Objective: To evaluate the application value of serum CA19-9, CEA, CA125 and CA242 in diagnosis andprognosis of pancreatic cancer cases treated with concurrent chemotherapy. Materials and
Methods: 52patients with pancreatic cancer, 40 with benign pancreatic diseases and 40 healthy people were selected. Theelectrochemiluminescence immunoassay method was used for detecting levels of CA19-9, CEA and CA125, anda CanAg CA242 enzyme linked immunoassay kit for assessing the level of CA242. The Kaplan-Meier methodwas used for analyzing the prognostic factors of patients with pancreatic cancer. The Cox proportional hazardmodel was applied for analyzing the hazard ratio (HR) and 95% confidential interval (CI) for survival timeof patients with pancreatic cancer.
Results: The levels of serum CA19-9, CEA, CA125 and CA242 in patientswith pancreatic cancer were significantly higher than those in patients with benign pancreatic diseases andhealthy people (P<0.001). The sensitivity of CA19-9 was the highest among these, followed by CA242, CA125and CEA. The specificity of CA242 is the highest, followed by CA125, CEA and CA19-9. The sensitivity andspecificity of joint detection of serum CA19-9, CEA, CA125and CA242 were 90.4% and 93.8%, obviouslyhigher than single detection of those markers in diagnosis of pancreatic cancer. The median survival time of52 patients with pancreatic cancer was 10 months (95% CI7.389~12.611).. Patients with the increasing level ofserum CA19-9, CEA, CA125, CA242 had shorter survival times (P=0.047. 0.043, 0.0041, 0.029). COX regressionanalysis showed that CA19-9 was an independent prognostic factor for patients with pancreatic cancer (P=0.001,95%CI 2.591~38.243).
Conclusions: The detection of serum tumor markers (CA19.9, CEA, CA125 and CA242)is conducive to the early diagnosis of pancreatic cancer and joint detection of tumor markers helps improve thediagnostic efficiency. Moreover, CA19-9 is an independent prognostic factor for patients with pancreatic cancer.